Tuesday, 07 Apr 2020

You are here

Skyrizi Outduels Humira in Psoriasis

A head-to-head trial has shown that risankizumab was significantly superior to adalimumab in providing skin clearance (PASI90) in patients with moderate-to-severe plaque psoriasis, with no difference in safety signals between the two agents. 

Risankizumab (Skyrizi), an interleukin-23 (IL-23) inhibitor, was FDA approved for use in psoriasis in April 2019, becoming the the third IL-23 inhibitor (includes guselkumab [Tremfya] and tildrakizumab [Ilumya]) approved in the last year for plaque psoriasis.

The IMMvent trial was a phase 3, randomised, double-blind, active-comparator-controlled trial that enrolled 605 adults with moderate-to-severe chronic plaque psoriasis and randomized them to either risankizumab (RIS) (150 mg subcutaneously at weeks 0 and 4 ) or adalimumab (ADA) (80 mg subcutaneously at randomisation, then 40 mg at weeks 1, 3, 5, and every other week thereafter during the first 16-weeks of the trial (part A). For weeks 16–44 (part B), adalimumab intermediate responders were re-randomised 1:1 to continue 40 mg adalimumab or switch to 150 mg risankizumab.

Co-primary endpoints in part A were a 90% improvement from baseline (PASI 90) and a static Physician's Global Assessment (sPGA) score of 0 or 1 at week 16.

Nearly all of the RIS (98%) and ADA (96%)patients completed part A (first 16 weeks) of the study. 

At week 16, PASI 90 results were:

  • RIS - 72%
  • ADA - 47% (p<0·0001)

In part B, at week 44, the ADA intermediate responders, achieved a PASI 90 in 66% of RIS treated patients and 21% in those continuing ADA therapy (p<0·0001).

Risankizumab showed significantly greater efficacy than adalimumab in providing skin clearance in moderate-to-severe plaque psoriasis.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

No Cancer Increase in Psoriatic Arthritis or with Biologics in Psoriasis

JAMA Dermatology reports that psoriasis is associated with a slightly increased risk of cancer, particularly keratinocyte cancer and lymphomas.

A systematic review and meta-analysis of 112 studies including more than 2 million patients, also shows no increase in when psoriasis is treated with biologic agents, nor was psoriatic arthritis associated with an increased risk of cancer.   

Bimekizumab Effective in Active Psoriatic Arthritis

Interleukin 17 IIL-17) is important in the pathogenesis of psoriatic disease, with most current approaches targeting IL-17A. Now there is a noveal approach showing that dual neutralisation of IL-17A and IL-17F in psoriatic arthritis arthritis patients results in clinically significant improvement.

Upadacitinib Effective in Phase 3 Psoriatic Arthritis Study

Abbvie has announced top line results of their SELECT-PSA trial of upadacitinib (UPA), wherein both the 15 and 30 mg doses met the primary endpoint of ACR20 response at week 12 and demonstrated radiographic inhibition at week 24.

Which Biologics are Best in Psoriasis

A metanalysis of phase II, III and IV trials in moderate to severe plaque psoriasis suggests comparative efficacy biologic treatments, but that that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were shown to have the past skin (PASI) response rates.

Taltz Shines in Non-Radiographic Axial Spondyloarthritis

Ixekizumab (IXE), an interleukin-17A (IL-17A) inhibitor, was recently approved for use in ankylosing spondylitis (also known as radiographic axial spondyloarthritis- axSpA). Lancet has published the results of the COAST-X study showing that ixekizumab was effective in patients with non-radiographic axial spondyloarthritis.